Data as of 2026-10-12.
"Blood cancer" covers three broad lineages: the leukemias (acute and chronic, myeloid and lymphoid), the lymphomas (Hodgkin and non-Hodgkin), and plasma-cell and myeloid neoplasms (multiple myeloma, MDS, myelofibrosis). These are the leading edge of cell and immune therapy, CAR-T, bispecific antibodies, and targeted small molecules, and many programs move across several subtypes at once. A complete hematologic view tracks the major lineages and the high-volume subtypes together.
Categories overlap (leukemia includes AML/ALL/CLL; the lymphoma total is the full lymphoma hub), so the rows below do not sum to the total above. Each links to a dedicated landscape page.
Major categories
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Leukemia (all types) | 2159 | 1244 | 191 |
| Lymphoma (all types) | 2323 | 1280 | 202 |
| Multiple Myeloma | 1033 | 554 | 122 |
| Myelodysplastic Syndromes (MDS) | 554 | 322 | 41 |
| Myelofibrosis | 142 | 83 | 14 |
Leukemia subtypes
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Acute Myeloid Leukemia (AML) | 994 | 578 | 94 |
| Acute Lymphoblastic Leukemia (ALL) | 755 | 449 | 58 |
| Chronic Lymphocytic Leukemia (CLL) | 391 | 187 | 44 |
Track every new blood cancer trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.
Get the free digest, no credit cardLargest industry-sponsored blood cancer trial portfolios by active study count:
| Industry sponsor | Active trials |
|---|---|
| Bristol-Myers Squibb | 49 |
| Johnson & Johnson / Janssen | 49 |
| AbbVie | 43 |
| AstraZeneca | 37 |
| Novartis Pharmaceuticals | 32 |
Our pipeline pulls from ClinicalTrials.gov every day. For a blood cancer watchlist or saved search, your digest covers:
- New study registrations and status changes (for example opened to recruiting, completed)
- Protocol changes: enrollment, endpoints, phase, and completion-date movements
- New sponsor entrants into a subtype
- Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
- Sponsor-type filters (large pharma vs. emerging biotech vs. academic)
Ready to automate your blood cancer trial monitoring?
Free plan, no credit card required. Set up your profile in 2 minutes.
Start freeFrequently asked questions
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top 2 trials), the weekly report (top 3 trials). No credit card.
Pro, $49/month or $490/year: 10 sponsor + 10 disease watchlists, 10 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list, Completions calendar, the full weekly report, landscape reports, CSV export.
Data as of 2026-10-12, from ClinicalTrials.gov. View the full pipeline on the dashboard.